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Objectives We compared the 5-year outcomes of diabetic patients with multivessel disease treated
with sirolimus-eluting stents (SES), bare-metal stents (BMS), and coronary artery bypass graft surgery
(CABG) enrolled in the ARTS (Arterial Revascularization Therapy Study) I and II studies.
Background Diabetes is an established risk factor for major adverse cardiac events after revascular-
ization. Recent trials suggest that revascularization with drug-eluting stents has equivalent safety to
CABG up to 2 years.
Methods The ARTS I and II studies included 367 diabetic patients (SES: 159, CABG: 96, and BMS:
112) compared with respect to 5-year clinical outcomes.
Results The rate of major adverse cardiovascular and cerebrovascular events was signiﬁcantly
higher in patients treated with BMS (BMS 53.6% vs. CABG 23.4% vs. SES 40.5%; log-rank, p  0.01
for SES vs. BMS and SES vs. CABG). There was no signiﬁcant difference in mortality among all 3
groups. There was, however, a statistically signiﬁcant difference in the myocardial infarction rate be-
tween BMS and CABG arms (BMS 11.0%, CABG 5.2%, SES 4.8%, p  0.04 for SES vs. BMS and p 
0.76 for SES vs. CABG). The rate of repeat revascularization was signiﬁcantly lower in patients treated
with CABG compared with SES (SES 33.2% vs. CABG 10.7%, p  0.001). Revascularization rate of pa-
tients treated with SES at 5 years approached that of patients treated with BMS although remained
signiﬁcantly lower. This “catch-up” phenomenon was not apparent in the nondiabetic population.
Conclusions At 5-year follow-up, CABG has comparable safety and superior efﬁcacy compared with
BMS and SES in the treatment of diabetic patients with multivessel disease. (J Am Coll Cardiol Intv
2011;4:317–23) © 2011 by the American College of Cardiology Foundation
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318Diabetes mellitus is an established risk factor for develop-
ment and progression of coronary atherosclerosis and is
associated with an increased incidence of major adverse
cardiac events (MACE) after revascularization (1,2). The
difference in MACE between diabetic and nondiabetic
patients treated with percutaneous revascularization has
consistently been driven by the higher rates of repeat
revascularization in diabetic patients (3,4). Similarly, among
See page 324
diabetic patients with multivessel disease (MVD) random-
ized to treatment with percutaneous coronary intervention
(PCI) or coronary artery bypass surgery (CABG), a corre-
spondingly higher rate of repeat revascularization has been
seen in those treated with PCI. With respect to mortality,
other than the BARI (Bypass Angioplasty Revascularization
Investigation) trial, which re-
ported a lower mortality with
CABG compared with balloon
angioplasty (5), more contempo-
rary studies report equivalent
mortality among diabetic pa-
tients with MVD treated with
CABG or PCI with either bare-
metal (BMS) or drug-eluting
stents (DES) (4,6–10).
At present there are limited
data on the long-term follow-up
of patients with diabetes and
MVD treated with DES. The
ARTS-I (Arterial Revasculariza-
tion Therapy Study Part I) and
ARTS-II studies both recruited
patients with MVD with the
same inclusion criteria (11,12). In
the ARTS-I study patients were
randomized to treatment with a BMS or CABG, whereas in
the single-arm ARTS-II study all patients received a sirolimus-
eluting stent (SES). The 3-year outcomes of 367 patients with
diabetes from the ARTS-I and ARTS-II studies have been
published previously (3). The aim of this report was to describe
the 5-year outcomes of this important subgroup of patients,
which consequently represents the longest reported follow-up
of diabetic patients with MVD treated with DES (3,4).
Methods
Study design. The ARTS-I and ARTS-II studies have
been published previously (11,12). In brief, the ARTS-II
study was a multicenter, nonrandomized, open-label trial
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CABG  coronary artery
bypass graft surgery
Ccr  creatinine clearance
DES  drug-eluting stent(s)
MACE  major adverse
cardiac event(s)
MACCE  major adverse
cardiac and cerebrovascular
event(s)
MI  myocardial infarction
MVD  multivessel disease
PCI  percutaneous
coronary intervention
SES  sirolimus-eluting
stent(s)designed to assess the safety and efficacy of SES in patients cwith native MVD and to compare the results with historical
control subjects enrolled in the ARTS-I study (3,12,13).
The inclusion and exclusion criteria for both studies were
the same. Patients with stable or unstable angina or silent
ischemia who had 2 coronary lesions located in different
major epicardial vessels and/or their side-branches (not
including the left main stem) that were potentially amenable
to stent implantation were eligible for inclusion. All patients
were required to have a lesion with a diameter stenosis
50% in the left anterior descending coronary artery and
1 other major epicardial coronary artery. Stents with a
diameter of 2.5 to 3.5 mm and length up to 33 mm were
used. The goal was to achieve complete anatomic revascu-
larization. There was no restriction on the total implanted
stent length. Decisions to place stents in lesions with
bifurcations, fresh thrombus, calcification, diffuse disease, or
complex anatomy or for stenting of side branches were left
to the discretion of the operators.
Patients with any prior coronary intervention, left main
coronary disease, overt congestive heart failure, or a left
ventricular ejection fraction 30% were excluded. Addi-
tional exclusion criteria included: history of a cerebrovascu-
lar accident, transmural myocardial infarction (MI) in the
preceding week, severe hepatic or renal disease, neutropenia
or thrombocytopenia, intolerance or contraindication to
acetylsalicylic acid or thienopyridines, need for concomitant
major surgery, and life-limiting major noncardiac diseases.
The study was approved by the ethical committees of each
participation institution. All patients signed informed con-
sent before study entry.
Patient population. In total, 367 diabetic patients (20.4% of
the overall ARTS I and II population) were studied in this
analysis, comprising the 208 diabetic patients enrolled in the
ARTS-I trial who were treated with BMS (n  112) or
CABG (n  96) and the 159 diabetic patients enrolled in
the ARTS-II trial treated with SES. In addition, compar-
ison is made with the nondiabetic patient cohort.
Study objectives and end points. The primary objectives of
the present analysis were to assess the long-term safety and
efficacy of the SES compared with BMS and CABG in
patients with diabetes and MVD. Comparison with the
nondiabetic population is also provided.
The primary end point of this study was 5-year major
adverse cardiac and cerebrovascular events (MACCE)—a
composite of death, stroke, MI, and repeat revascularization.
Other secondary end points included: death, stroke, MI, repeat
revascularization, and stent thrombosis at 5-year follow-up.
End points and deﬁnitions. Deaths from all causes were
eported. Cerebrovascular events included: stroke, transient
schemic attacks, and reversible ischemic neurologic deficits.
ithin 7 days after the intervention, a diagnosis of MI was
ade if new abnormal Q waves (according to the Minnesotaode) and either a ratio of serum creatine kinase-myocardial
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319band isoenzyme/total cardiac enzyme that was 0.1 or a
creatine kinase-myocardial band value that was 5 the
upper limit of normal were present. Serum creatine kinase
levels were measured 6 and 12 hours after the intervention
and before discharge. Beginning 8 days after the interven-
tion, either abnormal Q waves or enzymatic changes were
sufficient for a diagnosis of MI. This 2-part method of
defining MI was developed for the ARTS I study to address
the difficulty of diagnosing an MI after surgery. An MI was
confirmed only after the relevant electrocardiograms had
been analyzed by the electrocardiographic core laboratory.
All repeat revascularization procedures were recorded.
Events were counted from the time of the start of the
initial procedure. All clinical events were adjudicated by
the clinical events committee. Five-year clinical follow-up
was required in all patients and was obtained via a telephone
interview with the patient and, when needed, the physician
of the patient. The incidence of stent thrombosis according
to the Academic Research Consortium definitions was only
available for patients in the ARTS-II study (14). Renal
impairment was classified by estimated creatinine clearance
(Ccr) calculated by use of the Cockcroft–Gault formula
(15): Ccr (ml/min)  ([140  age]  weight [kg])/(serum
reatinine [mg/dl]  72). The formula was multiplied by a
actor of 0.85 for female patients. Patients who had Ccr
60 ml/min were regarded as having renal impairment.
mong 1,205 patients in the ARTS I study, 1,062 patients
88%) had their Ccr level before the revascularization,
Table 1. Baseline Clinical and Angiographic Characteristics
Diabetic Patients
BMS (n  112) SES (n  159) CABG (n 
Age in yrs, mean 63 65 63
Ejection fraction 61 60 60
Male 73 67 69
Diabetes insulin-treated 21 18 17
Hypertension 64 80 56
Hypercholesterolemia 55 74 49
Renal impairment* 15 5 15
Previous MI 41 30 49
Previous PCI 2 0 2
Current smoking 21 12 17
Unstable angina 38 32 33
Stable angina 59 54 63
Silent ischemia 4 15 4
2-vessel disease 65 49 64
3-vessel disease 31 50 35
Total number of implanted stent 3.0 1.5 3.6 1.5
Total stented length in mm 52.7 25.6 73.9 31.9
Max. stent pressure in atm 14.9 2.9 16.2 2.7
Values are % or mean SD, unless otherwise indicated.
BMSbare-metal stent(s); CABG coronary artery bypass graft; MImyocardial infarction; PCI(calculated by Cockcroft-Gault formula) were regarded as having renal impairment.hereas in the ARTS II study, 580 patients (96%) had Ccr
evel before procedure among 607 patients.
Statistical analysis. Baseline characteristics were compared for
diabetic patients in both the ARTS-I and ARTS-II trial.
Continuous variables are reported as mean  SD. Binary
ariable are reported as percentages with 95% confidence
ntervals. Two group t tests and Fisher tests were used for
ontinuous and discrete variables, respectively. Time-to-event
ariables are presented as Kaplan-Meier curves generated with
og-rank test. To compensate for differences in baseline and
rocedural characteristics between patients enrolled in the
RTS-I and ARTS-II trials, outcomes were adjusted with a
ox regression analysis with adjustments made for the poten-
ial confounding factors: age, sex, previous MI, history of
evascularization, CABG, insulin dependence (only for dia-
etic patients), current smoking, dyslipidemia, and hyperten-
ion. Post-hoc Bonferroni correction was performed for anal-
sis of variance. All analyses were performed with SPSS
oftware (SPSS, Chicago, Illinois).
esults
Baseline characteristics of diabetic patients. Baseline and
rocedural characteristics of the 367 diabetic patients en-
olled in the ARTS-I and ARTS-II trials are summarized in
able 1. Patients treated with SES were significantly more
ikely to be hypertensive and have hypercholesterolemia
nd complex coronary artery disease (type C lesions)
Nondiabetic Patients
p Value BMS (n  509) SES (n  448) CABG (n  488) p Value
0.12 60 62 61 0.01
0.81 61 60 60 0.66
0.53 78 80 77 0.56
0.78
0.01 40 63 43 0.01
0.01 59 74 59 0.01
0.01 13 4 14 0.01
0.01 41 36 41 0.02
0.17 1 1 2 0.10
0.15 30 22 28 0.02
0.64 38 38 38 1.00
0.35 56 53 57 0.45
0.01 7 9 5 0.04
0.01 69 45 67 0.01
0.01 27 55 29 0.01
0.01 2.7 1.2 3.7 1.5 0.01
0.01 46.4 20.6 72.0 32.1 0.01
0.01 14.6 2.8 16.4 2.9 0.01
taneous coronary intervention; SES sirolimus-eluting stent(s). *PatientswhohadCcr60ml/min96)
percu
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320compared with historical control subjects from the
ARTS-I trial. Consequently, a greater number of stents
and an overall longer total length was implanted in the
ARTS-II cohort. In addition, reported completeness of
revascularization was lower for patients treated with SES
Figure 1. Cumulative Kaplan-Meier Incidence Estimates Up to 5 Years
Cumulative Kaplan-Meier incidence estimates up to 5 years in diabetic subject
events (a composite of all-cause mortality, myocardial infarction [MI], cardi
MI (C); 4) for cerebrovascular accidents (D); 5) for a composite end point o
(F). BMS  bare-metal stent(s); CABG  coronary artery bypass graft; SES  siroversus BMS (68.6% for BMS vs. 59.9% for SES-treated
patients and 77.4% for CABG-treated patients with
diabetes; p  0.017).
Five-year clinical outcomes. Overall MACCE, death, MI,
erebrovascular accident, and repeat revascularization rates at 5
in nondiabetic subjects: 1) for major adverse cardiac and cerebrovascular
lar accident, or revascularization) (A); 2) for all-cause mortality (B); 3) for
h, cerebrovascular accidents, or MI (E); and 6) for any revascularizations and
ovascu
f deatlimus-eluting stent(s).
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321years are reported in Kaplan-Meier curves (Figs. 1A to 1F),
while crude event rates with unadjusted hazard ratios are
presented in Table 2. The event rates were higher than those
reported for the overall ARTS-I and ARTS-II populations
(16). The MACCE rate was the highest in patients
treated with BMS (BMS 53.8% vs. SES 40.5% vs.
CABG 23.4%; log-rank, p values for SES vs. BMS and
SES vs. CABG, p  0.001). Cumulative incidence of
all-cause mortality was 13.6%, 9.0%, and 8.6% for patients
treated with BMS, SES, and CABG, respectively (log-rank
for SES vs. BMS, p  0.23; SES vs. CABG, p  0.91).
he rate of MI was highest (11.0%) for BMS, versus 4.8%
or SES-treated patients and 5.2% for CABG patients
log-rank SES vs. BMS, p  0.04; SES vs. CABG, p 
.76), with a statistically significant difference between SES
nd BMS. There were no differences in the rates of
erebrovascular events between treatment groups at 5 years.
ates of repeat revascularization were the highest in the
MS revascularization group at 43.7% versus 33.2% in the
ES-treated group and 10.7% in the CABG group (log-
ank SES vs. BMS, p  0.02; SES vs. CABG, p  0.01).
In the SES group, clopidogrel use at 5 years was 13.2%
n diabetic patients and 23.2% in nondiabetic patients
p  0.008). Aspirin use was 68.6% in the diabetic patients
nd 77.7% in the nondiabetic patients (p  0.03).
Cox regression analysis. The HRs (adjusted for baseline
haracteristics) for CABG versus SES and BMS versus SES
re shown in Table 3. Treatment with BMS conferred
ignificantly higher risk of MACCE, death, MI, and repeat
evascularization than treatment with SES. Coronary artery
ypass graft surgery offered no advantage over treatment
ith SES in terms of mortality or risk of MI. There was
reduced risk of repeat revascularization and overall
revascularization driven) MACCE with CABG com-
ared with treatment with SES in diabetic patients.
imilar analysis in the nondiabetic population (Table 3)
howed equivalent HRs for MACCE and MI between
ABG and SES and higher mortality for CABG. Re-
ascularization rates remained higher in the SES group
hen compared with CABG, although the HR was 0.54
n the nondiabetic population versus 0.31 in the diabetic
opulation. The interaction, however, between treatment
ype and diabetic status was nonsignificant for all clinical
nd points.
Stent thrombosis. In diabetic patients treated with SES
here were 17 stent thrombosis events (10.7%), with 6
efinite, 6 probable, and 5 possible stent thrombosis events.
his is higher than the overall stent thrombosis rates
eported for the ARTS-II population of 9.4% and 8.7% for
he nondiabetic subgroup. The rate of definite stent throm-
osis in both the diabetic and nondiabetic patient popula-
ion was 3.8%. Two late and 2 very late stent thrombosis
ases occurred in the diabetic patient population. Twopatients with diabetes receiving SES (1.3% of 159) and 12T M D C M R C a
b
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322patients without diabetes receiving SES (2.7% of 448)
suffered from very late stent thrombosis.
Discussion
In this analysis we present the 5-year outcomes of PCI with
the SES in diabetic patients with MVD. At 3-year
follow-up of the ARTS-II trial, patients treated with SES
had lower MACCE rates than patients treated with BMS
PCI, and CABG in the ARTS-I trial, although the differ-
ences did not reach statistical significance (3). In contrast, at
5-year follow-up, MACCE rates were lowest for diabetic
patients treated with CABG in the ARTS-I trial. Patients
treated with SES had a MACCE rate lower than that of
patients treated with BMS PCI in the ARTS-I trial but
considerably higher than that of patients treated with
CABG. As illustrated by the Kaplan-Meier curves for
MACCE (Fig. 1A), although the event rate for patients
treated with BMS and CABG reach an asymptotic value at
1 year, events continue to accumulate for patients treated
with SES in the ARTS-II trial. After 2 years this increase
in events is partly explained by an increase in MI rates
(Fig. 1B). This “catch-up” phenomenon is much more
apparent in the diabetic population compared with nondi-
abetic patients (Table 3). The rate of repeat revasculariza-
tions also continues to accumulate, approaching closer to
that of the BMS-treated patients at 5 years (Fig. 1F). Cox
regression model HRs suggest an advantage of CABG over
SES in reducing repeat revascularization procedures but
equivalence of the 2 procedures in terms of mortality and
MI risk after adjusting for baseline covariates in patients
with diabetes (Table 3). The SES clearly reduced the risk of
MI, repeat revascularization, and overall MACCE but had
only a nonsignificant effect on mortality compared with
treatment with BMS. Overall stent thrombosis rate in the
diabetic population treated with DES is 10.7% at 5 years,
which is somewhat higher than that observed in the overall
ARTS-II population (9.4%). The rates of definite stent
Table 3. Adjusted HRs
Diabetic Patients
HR (95% CI)
CABG vs. SES p Value
HR (95% CI)
BMS vs. SES
Death 1.11 (0.47–2.66) 0.81 1.77 (0.85–3.67)
CVA 1.24 (0.42–3.65) 0.70 1.33 (0.49–3.59)
MI 1.19 (0.38–3.76) 0.76 2.55 (1.00–6.47)
Death/CVA/MI 1.33 (0.70–2.50) 0.38 2.09 (1.21–3.62)
Any Revasc. 0.31 (0.16–0.62) 0.001 1.61 (1.08–2.41)
MACCE 0.58 (0.36–0.95) 0.03 1.80 (1.25–2.57)
The Cox regression models are constructed to adjust the following variables: age, sex, previous
dyslipidemia, and hypertension.
Abbreviations as in Tables 1 and 2.thrombosis in diabetic and nondiabetic patients are thesame at 3.8% with two-thirds of the cases classified as late or
very late stent thrombosis.
Our analysis at 5-year follow-up agrees with other recent
trials, such as the CARDIA (Coronary Artery Revasculari-
sation in Diabetes) and SYNTAX (Synergy between Per-
cutaneous Coronary Intervention with TAXUS and Cardiac
Surgery) trials, which also demonstrate equivalent mortality
of PCI with DES and CABG in patients with diabetes at
1-year follow-up (4,9,10). Both of these studies also dem-
onstrate consistently higher revascularization rates in the
PCI arms versus CABG arm. The SYNTAX diabetic
subgroup analysis might have, however, been underpowered
to detect differences in mortality at 1 and 2 years. Our
results are also consistent with the BARI-2D (Bypass
Angioplasty Revascularization Investigation 2 Diabetes)
trial findings, where survival rates were similar between
PCI-treated and CABG-treated groups (86.4% for CABG
vs. 89.2% for PCI) at 5 years. The differences in the
MACE-free survival rate in patients with MVD random-
ized to CABG versus medical therapy were statistically
significant, but no such difference was appreciated in pa-
tients randomized to PCI versus medical therapy. Effective-
ness of PCI over medical therapy versus CABG will be
assessed in the FREEDOM (Future Revascularization
Evaluation in Patients with Diabetes Mellitus: Optimal
Management of Multivessel Disease) trial, the first properly
powered prospective trial of revascularization strategies in
diabetic patients.
Study limitations. This study is a sub-analysis of the main
ARTS-I and ARTS-II trials and hence suffers from inher-
ent limitations, such as the lack of sufficient power because
of the limited number of patients in the subgroups to
provide definite answers. Although the protocol required
that the lesions in the ARTS-II trial be potentially treatable
by CABG, the absence of dialogue with the surgeons before
the intervention might have caused a selection bias. Another
potential bias of this study is that a 5-year time difference
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323technology and medical practice have improved with time,
as have surgical mortality rates. The study is nonrandom-
ized, and consequently statistical adjustment is required to
correct for the differences between the current study popu-
lation and the historical ARTS-I population.
However, the results of the study after adjustment for
differences in risk factors did not substantially differ from
the unadjusted outcome, because the patients enrolled in the
ARTS-II trial were in fact more complex in terms of
demographic data and lesion characteristics than those
included in the ARTS-I trial. In addition, some of the
factors such as stent length used or willingness of the
operator to treat more complex lesions with DES or use of
dual antiplatelet agents could not be adjusted for and can be
a confounding factor in the analysis. Given low numbers of
events in some of the subgroups, the multivariate model
might have been overfitted.
Conclusions
When compared with the outcome of the diabetic patients
with MVD treated with either PCI or CABG, the overall
MACCE-free survival rate at 5 years in patients treated
with SES is higher than in patients treated with CABG
and, although still more favorable than in patients treated
with BMS, it seems to approach the rate of events in the
BMS-treated group. The MACCE rate in diabetic patients
treated with SES is predominantly driven by the rate of
repeat revascularization. The mortality in the SES-treated
population is similar to that of CABG patients at 5 years.
Myocardial infarction rate was 2-fold higher in diabetic
patients treated with BMS than in patients treated with
either SES or CABG. At 5-year follow-up, CABG seems
to have better outcomes than PCI in a diabetic patient
population by virtue of reducing repeat revascularization
rates, making CABG the preferred treatment for this
subgroup of patients with MVD.
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